Literature DB >> 25926099

Assessment of Tamsulosin 0.2 mg for Symptomatic Bladder Outlet Obstruction Secondary to Benign Prostatic Enlargement: Data from a Korean Multicenter Cross-Sectional Study.

Hoon Choi1, Ji Sung Sim, Jae Young Park, Jae Hyun Bae.   

Abstract

AIMS: To estimate efficacy and treatment satisfaction with tamsulosin 0.2 mg in patients with symptomatic bladder outlet obstruction secondary to benign prostatic enlargement and lower urinary tract symptoms in relation to personal satisfaction.
METHODS: The study was conducted in 1,260 subjects who were asked to fill in detailed questionnaires designed to evaluate their satisfaction with the treatment and symptom improvement 8 weeks after receiving tamsulosin 0.2 mg.
RESULTS: After being treated with tamsulosin 0.2 mg for 8 weeks, the International Prostate Symptom Score (IPSS) score improved significantly. Among the 1,260 patients, 813 (64.52%) were satisfied, while 447 (35.48%) were dissatisfied with tamsulosin 0.2 mg. The reasons for patient dissatisfaction were efficacy problems (79.87%) and side effects (4.25%). Treatment satisfaction was affected by age, underlying medical disease and baseline IPSS severity (p = 0.020, 0.0427 and <0.001, respectively), but only age and baseline IPSS were risk factors for dissatisfaction.
CONCLUSIONS: Tamsulosin 0.2 mg was effective in symptomatic improvement, but a relatively high proportion of patients were dissatisfied with the treatment. Efficacy problems were selected by patients as the main reason for dissatisfaction. It is also significant to note that the degree of satisfaction was related to age and baseline IPSS severity.
© 2015 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25926099     DOI: 10.1159/000366007

Source DB:  PubMed          Journal:  Urol Int        ISSN: 0042-1138            Impact factor:   2.089


  4 in total

1.  Evidence Is Enough?: A Systematic Review and Network Meta-Analysis of the Efficacy of Tamsulosin 0.2 mg and Tamsulosin 0.4 mg as an Initial Therapeutic Dose in Asian Benign Prostatic Hyperplasia Patients.

Authors:  Su Jin Kim; In-Soo Shin; Sung-Jong Eun; Taeg-Keun Whangbo; Jin Wook Kim; Young Sam Cho; Joon Chul Kim
Journal:  Int Neurourol J       Date:  2017-03-24       Impact factor: 2.835

2.  The Authors Reply: Reply on "Evidence Is Enough?: A Systematic Review and Network Meta-Analysis of the Efficacy of Tamsulosin 0.2 mg and Tamsulosin 0.4 mg as an Initial Therapeutic Dose in Asian Benign Prostatic Hyperplasia Patients".

Authors:  Su Jin Kim; In-Soo Shin; Sung-Jong Eun; Taeg-Keun Whangbo; Jin Wook Kim; Young Sam Cho; Joon Chul Kim
Journal:  Int Neurourol J       Date:  2017-09-12       Impact factor: 2.835

3.  Letter to the Editor: Commentary on "Evidence Is Enough?: A Systematic Review and Network Meta-Analysis of the Efficacy of Tamsulosin 0.2 mg and Tamsulosin 0.4 mg as an Initial Therapeutic Dose in Asian Benign Prostatic Hyperplasia Patients".

Authors:  Bum Sik Tae; Hoon Choi; Jae Hyun Bae
Journal:  Int Neurourol J       Date:  2017-09-12       Impact factor: 2.835

4.  Free combination of dutasteride plus tamsulosin for the treatment of benign prostatic hyperplasia in South Korea: analysis of drug utilization and adverse events using the National Health Insurance Review and Assessment Service database.

Authors:  Zrinka Lulic; Hwancheol Son; Sang-Bae Yoo; Marianne Cunnington; Pratiksha Kapse; Diane Miller; Vanessa Cortes; Suna Park; Rachel H Bhak; Mei Sheng Duh
Journal:  BMC Urol       Date:  2021-12-21       Impact factor: 2.264

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.